Septerna (SEPN) Total Liabilities (2023 - 2026)
Septerna's quarterly Total Liabilities came in at $191.2 million in Q1 2026, up 466.54% year-on-year from $33.8 million in Q1 2025, and down 10.75% quarter-over-quarter from $214.3 million in Q4 2025.
Septerna has reported Total Liabilities for 4 years, with the latest figure at $191.2 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 466.54% year-over-year to $191.2 million; the trailing twelve-month figure through Mar 2026 stood at $191.2 million (up 466.54% YoY), and the FY2025 full-year result was $214.3 million, up 486.9% from the prior year.
- Total Liabilities for Q1 2026 stood at $191.2 million, down from $214.3 million in the prior quarter.
- The five-year high for Total Liabilities was $217.9 million in Q3 2025, with the low at $20.0 million in Q4 2023.
- Average Total Liabilities over 4 years is $89.3 million, with a median of $51.9 million recorded in 2024.
- Year-over-year, Total Liabilities tumbled 49.18% in 2024 and jumped 486.9% in 2025.
- Tracing SEPN's Total Liabilities over 4 years: stood at $20.0 million in 2023, then soared by 82.3% to $36.5 million in 2024, then jumped by 486.9% to $214.3 million in 2025, then declined by 10.75% to $191.2 million in 2026.
- The last three Total Liabilities figures came in at $191.2 million (Q1 2026), $214.3 million (Q4 2025), and $217.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 191.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 191.23 Mn |
| Dec 31, 2025 | 214.26 Mn |
| Sep 30, 2025 | 217.92 Mn |
| Jun 30, 2025 | 37.67 Mn |
| Mar 31, 2025 | 33.75 Mn |
| Dec 31, 2024 | 36.51 Mn |
| Sep 30, 2024 | 37.53 Mn |
| Jun 30, 2024 | 67.76 Mn |
| Mar 31, 2024 | 51.89 Mn |
| Dec 31, 2023 | 20.03 Mn |
| Sep 30, 2023 | 73.85 Mn |